Biologically Targeted Radiation Therapy: Incorporating Patient-Specific Hypoxia Data Derived from Quantitative Magnetic Resonance Imaging

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Oct 13

PMID 34638382

Citations 7

Authors

Emily J Her

Annette Haworth

Yu Sun

Scott Williams

Hayley M Reynolds

Angel Kennedy

Martin A Ebert

Affiliations

Soon will be listed here.

Abstract

Purpose: Hypoxia has been linked to radioresistance. Strategies to safely dose escalate dominant intraprostatic lesions have shown promising results, but further dose escalation to overcome the effects of hypoxia require a novel approach to constrain the dose in normal tissue.to safe levels. In this study, we demonstrate a biologically targeted radiotherapy (BiRT) approach that can utilise multiparametric magnetic resonance imaging (mpMRI) to target hypoxia for favourable treatment outcomes.

Methods: mpMRI-derived tumour biology maps, developed via a radiogenomics study, were used to generate individualised, hypoxia-targeting prostate IMRT plans using an ultra- hypofractionation schedule. The spatial distribution of mpMRI textural features associated with hypoxia-related genetic profiles was used as a surrogate of tumour hypoxia. The effectiveness of the proposed approach was assessed by quantifying the potential benefit of a general focal boost approach on tumour control probability, and also by comparing the dose to organs at risk (OARs) with hypoxia-guided focal dose escalation (DE) plans generated for five patients.

Results: Applying an appropriately guided focal boost can greatly mitigate the impact of hypoxia. Statistically significant reductions in rectal and bladder dose were observed for hypoxia-targeting, biologically optimised plans compared to isoeffective focal DE plans.

Conclusion: Results of this study suggest the use of mpMRI for voxel-level targeting of hypoxia, along with biological optimisation, can provide a mechanism for guiding focal DE that is considerably more efficient than application of a general, dose-based optimisation, focal boost.

Citing Articles

A review of whole gland prostate brachytherapy with focal dose escalation to intra-prostatic lesions: Clinical efficacy and technical aspects.

Poder J, Hoskin P, Reynolds H, Him Chan T, Haworth A Phys Imaging Radiat Oncol. 2024; 32:100645.

PMID: 39381615 PMC: 11459009. DOI: 10.1016/j.phro.2024.100645.

Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer.

Davoudi F, Moradi A, Becker T, Lock J, Abbey B, Fontanarosa D Curr Treat Options Oncol. 2023; 24(10):1451-1471.

PMID: 37561382 PMC: 10547634. DOI: 10.1007/s11864-023-01121-z.

Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy.

Him Chan T, Haworth A, Wang A, Osanlouy M, Williams S, Mitchell C EJNMMI Res. 2023; 13(1):34.

PMID: 37099047 PMC: 10133419. DOI: 10.1186/s13550-023-00984-5.

Radiogenomics Reveals Correlation between Quantitative Texture Radiomic Features of Biparametric MRI and Hypoxia-Related Gene Expression in Men with Localised Prostate Cancer.

Ogbonnaya C, Alsaedi B, Alhussaini A, Hislop R, Pratt N, Nabi G J Clin Med. 2023; 12(7).

PMID: 37048688 PMC: 10095552. DOI: 10.3390/jcm12072605.

Prostate Cancer: Pathophysiology, Pathology and Therapy.

Tzelepi V Cancers (Basel). 2023; 15(1).

PMID: 36612276 PMC: 9818719. DOI: 10.3390/cancers15010281.

References

Wang J, Li X, Mayr N . Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data. Br J Radiol. 2006; 79(947):905-11. DOI: 10.1259/bjr/18700614. View

Ruggieri R, Naccarato S, Nahum A . Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia. Acta Oncol. 2010; 49(8):1304-14. DOI: 10.3109/0284186X.2010.486796. View

Thorwarth D, Eschmann S, Paulsen F, Alber M . A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys. 2007; 68(2):515-21. DOI: 10.1016/j.ijrobp.2006.12.037. View

Paczkowski M, Kretzschmar W, Markelc B, Liu S, Kunz-Schughart L, Harris A . Reciprocal interactions between tumour cell populations enhance growth and reduce radiation sensitivity in prostate cancer. Commun Biol. 2021; 4(1):6. PMC: 7782740. DOI: 10.1038/s42003-020-01529-5. View

Her E, Haworth A, Reynolds H, Sun Y, Kennedy A, Panettieri V . Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI. Radiat Oncol. 2020; 15(1):172. PMC: 7805066. DOI: 10.1186/s13014-020-01568-6. View

Haworth A, Ebert M, Waterhouse D, Joseph D, Duchesne G . Assessment of i-125 prostate implants by tumor bioeffect. Int J Radiat Oncol Biol Phys. 2004; 59(5):1405-13. DOI: 10.1016/j.ijrobp.2004.01.047. View

Draulans C, van der Heide U, Haustermans K, Pos F, van der Voort van Zyp J, de Boer H . Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020; 147:92-98. DOI: 10.1016/j.radonc.2020.03.015. View

Haworth A, Mears C, Betts J, Reynolds H, Tack G, Leo K . A radiobiology-based inverse treatment planning method for optimisation of permanent l-125 prostate implants in focal brachytherapy. Phys Med Biol. 2015; 61(1):430-44. DOI: 10.1088/0031-9155/61/1/430. View

Kron T, Thomas J, Fox C, Thompson A, Owen R, Herschtal A . Intra-fraction prostate displacement in radiotherapy estimated from pre- and post-treatment imaging of patients with implanted fiducial markers. Radiother Oncol. 2010; 95(2):191-7. DOI: 10.1016/j.radonc.2010.01.010. View

10.

Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A . Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res. 2012; 18(7):2108-14. DOI: 10.1158/1078-0432.CCR-11-2711. View

11.

Her E, Ebert M, Kennedy A, Reynolds H, Sun Y, Williams S . Standard versus hypofractionated intensity-modulated radiotherapy for prostate cancer: assessing the impact on dose modulation and normal tissue effects when using patient-specific cancer biology. Phys Med Biol. 2020; 66(4):045007. DOI: 10.1088/1361-6560/ab9354. View

12.

Terraneo L, Bianciardi P, Caretti A, Ronchi R, Samaja M . Chronic systemic hypoxia promotes LNCaP prostate cancer growth in vivo. Prostate. 2010; 70(11):1243-54. DOI: 10.1002/pros.21160. View

13.

Sun Y, Reynolds H, Parameswaran B, Wraith D, Finnegan M, Williams S . Multiparametric MRI and radiomics in prostate cancer: a review. Australas Phys Eng Sci Med. 2019; 42(1):3-25. DOI: 10.1007/s13246-019-00730-z. View

14.

Gordon J, Siebers J . Evaluation of dosimetric margins in prostate IMRT treatment plans. Med Phys. 2008; 35(2):569-75. PMC: 2663592. DOI: 10.1118/1.2826558. View

15.

Butterworth K, McCarthy H, Devlin A, Ming L, Robson T, McKeown S . Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer. 2008; 123(4):760-8. DOI: 10.1002/ijc.23418. View

16.

Alqawi O, Wang H, Espiritu M, Singh G . Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells. Free Radic Res. 2007; 41(7):788-97. DOI: 10.1080/10715760701361531. View

17.

Supiot S, Rousseau C, Dore M, Cheze-le-Rest C, Kandel-Aznar C, Potiron V . Reoxygenation during radiotherapy in intermediate-risk prostate cancer. Radiother Oncol. 2019; 133:16-19. DOI: 10.1016/j.radonc.2018.12.022. View

18.

Jeong J, Shoghi K, Deasy J . Modelling the interplay between hypoxia and proliferation in radiotherapy tumour response. Phys Med Biol. 2013; 58(14):4897-919. PMC: 4784425. DOI: 10.1088/0031-9155/58/14/4897. View

19.

Sun Y, Reynolds H, Wraith D, Williams S, Finnegan M, Mitchell C . Voxel-wise prostate cell density prediction using multiparametric magnetic resonance imaging and machine learning. Acta Oncol. 2018; 57(11):1540-1546. DOI: 10.1080/0284186X.2018.1468084. View

20.

Niemierko A . Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997; 24(1):103-10. DOI: 10.1118/1.598063. View